Low Dose Rapamycin in ME/CFS, Long-COVID, and Other Infection Associated Chronic Conditions

Enrolling by invitation

Conditions studied: Myalgic Encephalomyelitis, Long-COVID

In brief

The goal of this observational study is to assess the clinical response and the effect of autophagy function in patients before, during and throughout oral low dose sirolimus (rapamycin) therapy. The main questions this study aims to answer are: * Does rapamycin reduce the overall symptom burden in this patient population and does it improve the quality of life? * Does rapamycin change mTOR driven autophagy deficits observed in a subset of patients? Participants will be asked to complete a series of questionnaires and quality of life instruments before starting rapamycin therapy prescribed by their physician and throughout their course of treatment. Study blood samples will be collected before starting therapy and throughout the course of treatment to assess serological markers of autophagy function.

Key facts

Study ID

NCT06257420

Run by

Simmaron Research Inc.

People needed

150

Starts

2023-12-11

Expected to finish

2027-07-01

Last updated by the study team

2026-05-18

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of ME/CFS that meets the Institute of Medicine (IOM) criteria
• Diagnosis of Long-COVID (PASC clinical criteria)

You may not qualify if…

• No diagnosis of ME/CFS or Long-COVID

Where it is running

• Center For Complex Diseases — Palo Alto, California, United States
• The Mayo Clinic — Rochester, Minnesota, United States
• Sierra Internal Medicine — Incline Village, Nevada, United States
• Bateman Horne Center — Salt Lake City, Utah, United States
• Center For Complex Diseases — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.